



Klaria receives additional subscription commitments and extends the subscription period in the Company's rights issue

Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that the Company has received approximately SEK 2.2 million in subscription commitments without preferential rights in the ongoing rights issue of units of up to approximately SEK 147.6 million (the "Rights Offering"). No compensation will be paid for these subscription commitments, and they are included within the framework of the existing guarantee structure of a total of approx. SEK 111.1 million, corresponding to 75.3 percent of the Rights Offering. Furthermore, the Board of Directors has decided to extend the subscription period until November 6, 2026 in light of a strong interest from shareholders and investors and the accompanying request for extended time to have the opportunity to subscribe for units in the Rights Offering with preferential rights.

Below is an updated timetable for the Rights Offering. As a result of the extended subscription period, the period for trading in unit rights is also extended to November 3. All other terms and conditions remain as before.

Event	Date
Trading in unit rights	October 14-November 3, 2026
Subscription period	October 14-November 6, 2026
Trading in paid subscribed units (BTU)	October 14-November 24, 2026
Expected announcement of the preliminary outcome	November 9, 2026
Expected announcement of the final outcome	November 10, 2026

More information about the Rights Offering can be found on the Company's website, www.klaria.com, and on the issue page www.ii.se/klaria-rights-issue-of-units-2026/

For more information, visit the Klaria Pharma Holding website klaria.com or contact:

Fredrik Hübinette, Chairman of the Board of Directors

info@klaria.com

Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.